Recruiting
Study on Zanubrutinib and Rituximab for Patients with IgM Monoclonal Gammopathy and MAG Antibodies-Related Polyneuropathy
Registered drugNo placebo
Study on Zanubrutinib and Rituximab for Patients with IgM Monoclonal Gammopathy and MAG Antibodies-Related Polyneuropathy
Registered drugNo placebo
- Disease:Anti-myelin-associated glycoprotein associated polyneuropathy
- Substances:Zanubrutinib
Countries:
The Netherlands
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Zanubrutinib
- Sponsor:Universitair Medisch Centrum Utrecht

